Immutep (IMMP) News Today → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free IMMP Stock Alerts $2.82 -0.11 (-3.75%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:00 AM | globenewswire.comImmutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024May 11, 2024 | americanbankingnews.comImmutep (NASDAQ:IMMP) Shares Pass Above 50 Day Moving Average of $2.57May 2, 2024 | globenewswire.comPositive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaMay 1, 2024 | seekingalpha.comImmutep: Realizing The Expected Catalysts, With More To ComeApril 29, 2024 | globenewswire.comImmutep Quarterly Activities Report Q3 FY24April 26, 2024 | markets.businessinsider.comImmutep’s Efti Shows Promise in Cancer Therapy, Analyst Maintains Buy RatingApril 25, 2024 | markets.businessinsider.comImmutep Buy Rating Justified by Strong Clinical Trial Results and Promising Future ProspectsApril 24, 2024 | markets.businessinsider.comImmutep Reports Positive Preliminary Topline Results From TACTI-003 Cohort BApril 24, 2024 | msn.comImmutep reports promising efti/Keytruda data for head and neck cancerApril 24, 2024 | globenewswire.comImmutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort BApril 19, 2024 | finance.yahoo.comMutual Fund Series Trust - Alphacentric Municipal Opportunities Fund (MUNIX)April 18, 2024 | globenewswire.comImmutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761April 17, 2024 | globenewswire.comImmutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerApril 15, 2024 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Short Interest Up 10.5% in MarchImmutep Limited (NASDAQ:IMMP - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 1,260,000 shares, a growth of 10.5% from the March 15th total of 1,140,000 shares. Based on an average daily volume of 141,400 shares, the days-to-cover ratio is currently 8.9 days.March 9, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average of $2.35Immutep (NASDAQ:IMMP) Shares Pass Above 50 Day Moving Average of $2.35March 7, 2024 | edition.cnn.comImmutep Ltd Sponsored ADRMarch 1, 2024 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Holdings Cut by Oracle Investment Management Inc.Oracle Investment Management Inc. trimmed its stake in Immutep Limited (NASDAQ:IMMP - Free Report) by 42.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 516,430 shares of the biotechnology company's stock afteFebruary 23, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average of $2.33Immutep (NASDAQ:IMMP) Shares Pass Below Fifty Day Moving Average of $2.33February 2, 2024 | marketbeat.comImmutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average of $2.25Immutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average of $2.25February 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immutep on Strong Clinical Pipeline and Market PotentialJanuary 15, 2024 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Short Interest UpdateImmutep Limited (NASDAQ:IMMP - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 540,200 shares, an increase of 51.4% from the December 15th total of 356,700 shares. Based on an average daily trading volume, of 180,800 shares, the short-interest ratio is currently 3.0 days.January 13, 2024 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Sees Large Increase in Short InterestImmutep Limited (NASDAQ:IMMP - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 540,200 shares, an increase of 51.4% from the December 15th total of 356,700 shares. Based on an average daily volume of 180,800 shares, the short-interest ratio is presently 3.0 days.January 4, 2024 | finance.yahoo.comFirst Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerJanuary 3, 2024 | seekingalpha.comImmutep: Upcoming Signals For 2024 (Maintain Buy)December 28, 2023 | marketbeat.comMeridian Wealth Management LLC Purchases 48,150 Shares of Immutep Limited (NASDAQ:IMMP)Meridian Wealth Management LLC increased its position in shares of Immutep Limited (NASDAQ:IMMP - Free Report) by 18.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 311,200 shares of the biotechnology company's stoDecember 24, 2023 | finance.yahoo.comImmutep Limited (IMMP)December 17, 2023 | marketbeat.comImmutep Limited (NASDAQ:IMMP) Sees Significant Decline in Short InterestImmutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 344,700 shares, a drop of 8.1% from the November 15th total of 375,200 shares. Based on an average daily trading volume, of 143,600 shares, the short-interest ratio is presently 2.4 days.November 6, 2023 | finance.yahoo.comImmutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNovember 3, 2023 | finanznachrichten.deImmutep Limited: Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 3, 2023 | markets.businessinsider.comImmutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNovember 2, 2023 | finance.yahoo.comImmutep to Participate in November Investor EventsOctober 27, 2023 | markets.businessinsider.comBuy Rating for Immutep (IMMP) Supported by Strong Phase 2 Study Results and Solid Financial PositionOctober 25, 2023 | msn.comImmutep receives about A$1.13M R&D tax incentive from Australian govtOctober 25, 2023 | finance.yahoo.comImmutep receives ~A$1.13 million R&D Tax IncentiveOctober 24, 2023 | finance.yahoo.comImmutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023October 23, 2023 | stockhouse.comImmutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerOctober 22, 2023 | markets.businessinsider.comImmutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLCOctober 3, 2023 | finance.yahoo.comImmutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingSeptember 5, 2023 | finance.yahoo.comImmutep to Participate in September Investor ConferencesAugust 30, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)August 3, 2023 | msn.comImmutep Limited - ADR (IMMP) Price Target Increased by 21.21% to 2.84August 1, 2023 | finance.yahoo.comImmutep Receives Positive Scientific Advice from European Medicines AgencyJune 20, 2023 | finance.yahoo.comImmutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3June 5, 2023 | benzinga.comImmutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual MeetingJune 3, 2023 | au.finance.yahoo.comIMMP - Immutep LimitedJune 2, 2023 | finance.yahoo.comImmutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement OfferMay 31, 2023 | marketbeat.comTrading was temporarily halted for "IMMP" at 06:05 AM with a stated reason of "News pending."May 18, 2023 | msn.comMaxim Group Maintains Buy Rating for Immutep: Here's What You Need To KnowMay 18, 2023 | finance.yahoo.comImmutep (IMMP) Surges 65% on Upbeat Lung Cancer Study DataMay 17, 2023 | msn.comImmutep Soars with New Cancer Treatment Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. IMMP Media Mentions By Week IMMP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMP News Sentiment▼0.650.55▲Average Medical News Sentiment IMMP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMP Articles This Week▼41▲IMMP Articles Average Week Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Pyxis Oncology News 2seventy bio News Design Therapeutics News Werewolf Therapeutics News Aldeyra Therapeutics News 23andMe News Foghorn Therapeutics News Veru News Nektar Therapeutics News Conduit Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMP) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHow to Play the AI and Crypto Markets in One SwingWeiss RatingsAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
